Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody

Chad E. Mire, Joan B. Geisbert, Viktoriya Borisevich, Karla A. Fenton, Krystle N. Agans, Andrew I. Flyak, Daniel J. Deer, Herta Steinkellner, Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, Do H. Kim, Michael H. Pauly, Jesus Velasco, Kevin J. Whaley, James E. Crowe, Larry Zeitlin, Thomas W. Geisbert

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.

Original languageEnglish (US)
Article numbereaai8711
JournalScience Translational Medicine
Issue number384
StatePublished - Apr 5 2017

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody'. Together they form a unique fingerprint.

Cite this